Evidence map›Paper›PMID 32189930›Full record

ArticleJournal of clinical and experimental hepatology

Entecavir is Safe and Effective in Long Term for the Treatment of Hepatitis B in Immunocompromised Children.

Manzoor A Wani, Jaswinder S Sodhi, Showkat A Zargar, Ghulam N Yatoo, Altaf Shah, Sheikh A Aziz, Sajad Geelani, Inaamul Haq, Ghulam M Gulzar, Mushtaq Khan and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Manzoor A WaniGastroenterology and Hepatology, Jawahar Lal Nehru Memorial Hospital(JLNMH), Rainawari, Srinagar, J&K, India.
Jaswinder S SodhiDepartment of Gastroenterology and Hepatology, Sheri Kashmir Institute of Medical Sciences(SKIMS), India.
Showkat A ZargarDepartment of Gastroenterology and Hepatology, Sheri Kashmir Institute of Medical Sciences(SKIMS), India.
Ghulam N YatooDepartment of Gastroenterology and Hepatology, Sheri Kashmir Institute of Medical Sciences(SKIMS), India.
Altaf ShahDepartment of Gastroenterology and Hepatology, Sheri Kashmir Institute of Medical Sciences(SKIMS), India.
Sheikh A AzizDepartment of Medical Oncology, SKIMS, India.
Sajad GeelaniDepartment of Clinical Hematology, SKIMS, India.
Inaamul HaqDepartment of Community Medicine, GMC Srinagar, India.
Ghulam M GulzarDepartment of Gastroenterology and Hepatology, Sheri Kashmir Institute of Medical Sciences(SKIMS), India.
Mushtaq KhanDepartment of Gastroenterology and Hepatology, Sheri Kashmir Institute of Medical Sciences(SKIMS), India.
Inaamul HaqDepartment of Community Medicine, Government Medical College (GMC), Jammu and Kashmir, Bemina, Srinagar, 190010, India.
Sher-i-Kashmir Institute of Medical Sciences · INGovernment Medical College · INKamla Nehru Memorial Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveHepatitis B infection is common in patients with cancer, and prompt treatment is necessary; otherwise, it can result in life-threatening complications. The objective of this study was to assess the long-term safety and efficacy of entecavir in immunocompromised children with hepatitis B.

methodsThis single-center prospective study was conducted on children with different malignancies referred to our department with evidence of hepatitis B infection. Only those children were included in the study who had HBsAg positive and alanine aminotransferase (ALT) more than 2 times the upper limit of normal and whose hepatitis B virus (HBV) DNA was more than 20,000IU/ml. These children were put on entecavir and prospectively observed upto 192 weeks. Primary efficacy end point was the proportion of patients who achieved undetectable HBV DNA at 48 weeks of treatment. Other efficacy end points were the proportion of patients with HBeAg seroconversion, undetectable HBV DNA, and ALT normalization at weeks 48 and 96 weeks.

resultsA total of 41 children met the inclusion criteria, of which 5 children died because of malignancy and 5 were lost to follow-up. Mean log DNA was 7.67 at the start which after starting entecavir reduced to 4.1, 2.8, 1.19, 1.09, and 0.84 at 12, 24, 48, 72, and 96 weeks, respectively (

conclusionEntecavir is safe and effective in long term for the treatment of hepatitis B in immunocompromised children.

Indexed as

AASLD, American Association of Study of Liver DiseasesADR, adverse drug reactionALT, alanine aminotransferaseCHB, chronic hepatitis BchemotherapyCT, chemotherapyEASL, European Association of Study of LiverHBV, hepatitis B virusHBVR, hepatitis B virus reactivationHCC, hepatocellular carcinomaINASL, Indian National Association of Study of LiverPCR, polymerase chain reactionreactivationTAF, tenofovir alafenamidetransfusionUSG, ultrasonography

Identifiers

PMID32189930
PMCPMC7067991
OpenAlexW2938840539

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.